Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

BMC Pulmonary Medicine

Chao-Liang Wu¹  Chian-Wei Chen²  Chin-Wei Kuo³  Tang-Hsiu Huang³  Yau-Lin Tseng⁴  Sheng-Hsiang Lin⁵ 

[1] Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Division of Thoracic Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;

关键词: Nintedanib;    Krebs von den Lungen-6;    Surfactant protein A;    Diffusion capacity for carbon monoxide;    Acute exacerbation;    Mortality;   

DOI  :  10.1186/s12890-021-01530-6

来源: Springer

【 授权许可】

CC BY